MedPath

Compare the Operating Condition of Two Levels of Muscle Relaxation on Facial Nerve MEP Monitoring in CPA Surgery

Not Applicable
Completed
Conditions
Cerebellopontine Angle Tumor
Interventions
Drug: Rocroniom, Non Depolarizing Muscle Relaxant
Registration Number
NCT04148534
Lead Sponsor
Muhammad Magdy Gaber
Brief Summary

compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery .

* To Estimate End to start facial nerve MEP amplitude ratio

* To determine the effect of neuromuscular relaxant degrees on recovery and

* Assessment of propofol doses needed for enhancement of early recovery and ambulation.

Detailed Description

40 Patients aged from 18-60 years old undergoing Cerebellopontine angle surgery. Patients will be one of two groups: Both Induction will be accomplished with fentanyl, propofol , rocronium infusion will be given randomly to one of the groups.

Depth of anaesthesia, neurotransmitter monitoring and facial nerve neurophysiological monitoring will be done.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patients age between >18 and<60.
  • Patients scheduled for neurosurgical CPA surgeries
  • Ability to sign the consent
  • ASA classification I, II
Exclusion Criteria
  • ASA > II
  • Hemodynamically unstable
  • Disease affecting neuromuscular transmission (myasthenia gravies ...etc.)
  • GCS < 15.
  • Any cardiac patient (ischemic heart disease - cardiomyopathy...etc.)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
muscle relaxantRocroniom, Non Depolarizing Muscle Relaxantpatient who will receive muscle relaxant, patients will receive rocronium infusion by (5 mcg/kg/min) , maintain partial NMB TOF count 2 and targeting BIS = (40-60)
without muscle relaxantRocroniom, Non Depolarizing Muscle Relaxantpatient who will not receive muscle relaxant, will recieve normal saline targeting BIS = 40-60.
Primary Outcome Measures
NameTimeMethod
End to start facial nerve MEP amplitude ratio.6 to 8 month

TCMEP recording will begin (1) prior to skin incision as baseline amplitude before muscle relaxant be taken for intubation (2) at Dural closure and end \\start amplitude ratio will be calculated.

Secondary Outcome Measures
NameTimeMethod
number of hypotension episodes and the use of vasopressors6 to 8 month

hemodynamic condition

Total volume of propofol and fentanyl infused6 to 8 month

Calculate dose consumption

Trial Locations

Locations (1)

Cairo university medical school

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath